Literature DB >> 25218565

Bioinorganic chemistry of synucleinopathies: deciphering the binding features of Met motifs and His-50 in AS-Cu(I) interactions.

Marco C Miotto1, Andrés Binolfi2, Markus Zweckstetter3, Christian Griesinger4, Claudio O Fernández5.   

Abstract

The aggregation of alpha-synuclein (AS) is a critical step in the etiology of Parkinson's disease (PD) and other neurodegenerative synucleinopathies. This process is selectively enhanced by copper in vitro and the interaction is proposed to play a potential role in vivo. Presently, the identity of the Cu(I) binding sites in AS and their relative affinities are under debate. In this work we have addressed unresolved details related to the structural binding specificity and affinity of Cu(I) to full-length AS. We demonstrated conclusively that: (i) the binding preferences of Cu(I) for the Met-binding sites at the N- (Kd=20 μM) and C-terminus (Kd=270 μM) of AS are widely different: (ii) the imidazole ring of His-50 acts as an effective anchoring residue (Kd=50 μM) for Cu(I) binding to AS; and (iii) no major structural rearrangements occur in the protein upon Cu(I) binding. Overall, our work shows that Cu(I) binding to the N- and C-terminal regions of AS are two independent events, with substantial differences in their affinities, and suggest that protein oxidative damage derived from a misbalance in cellular copper homeostasis would target preferentially the N-terminal region of AS. This knowledge is key to understanding the structural-aggregation basis of the copper catalyzed oxidation of AS.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alpha-synuclein; Cu(I); Met-rich sites; Parkinson

Mesh:

Substances:

Year:  2014        PMID: 25218565     DOI: 10.1016/j.jinorgbio.2014.08.012

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  7 in total

Review 1.  Coherent and Contradictory Facts, Feats and Fictions Associated with Metal Accumulation in Parkinson's Disease: Epicenter or Outcome, Yet a Demigod Question.

Authors:  Mohd Sami Ur Rasheed; Sonam Tripathi; Saumya Mishra; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2016-08-01       Impact factor: 5.590

Review 2.  α-Synuclein in Parkinson's disease: causal or bystander?

Authors:  Peter Riederer; Daniela Berg; Nicolas Casadei; Fubo Cheng; Joseph Classen; Christian Dresel; Wolfgang Jost; Rejko Krüger; Thomas Müller; Heinz Reichmann; Olaf Rieß; Alexander Storch; Sabrina Strobel; Thilo van Eimeren; Hans-Ullrich Völker; Jürgen Winkler; Konstanze F Winklhofer; Ullrich Wüllner; Friederike Zunke; Camelia-Maria Monoranu
Journal:  J Neural Transm (Vienna)       Date:  2019-06-25       Impact factor: 3.575

3.  Role of N-terminal methionine residues in the redox activity of copper bound to alpha-synuclein.

Authors:  Esaú E Rodríguez; Trinidad Arcos-López; Lidia G Trujano-Ortiz; Claudio O Fernández; Felipe J González; Alberto Vela; Liliana Quintanar
Journal:  J Biol Inorg Chem       Date:  2016-07-15       Impact factor: 3.358

4.  Cu and Zn coordination to amyloid peptides: From fascinating chemistry to debated pathological relevance.

Authors:  Elena Atrián-Blasco; Paulina Gonzalez; Alice Santoro; Bruno Alies; Peter Faller; Christelle Hureau
Journal:  Coord Chem Rev       Date:  2018-09-15       Impact factor: 22.315

Review 5.  α-Synuclein: An All-Inclusive Trip Around its Structure, Influencing Factors and Applied Techniques.

Authors:  Nicolò Bisi; Lucia Feni; Kaliroi Peqini; Helena Pérez-Peña; Sandrine Ongeri; Stefano Pieraccini; Sara Pellegrino
Journal:  Front Chem       Date:  2021-07-07       Impact factor: 5.221

Review 6.  Neurometals in the Pathogenesis of Prion Diseases.

Authors:  Masahiro Kawahara; Midori Kato-Negishi; Ken-Ichiro Tanaka
Journal:  Int J Mol Sci       Date:  2021-01-28       Impact factor: 5.923

Review 7.  Amyloids: Regulators of Metal Homeostasis in the Synapse.

Authors:  Masahiro Kawahara; Midori Kato-Negishi; Ken-Ichiro Tanaka
Journal:  Molecules       Date:  2020-03-23       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.